I’m a little late getting going today… I’d like to say that I’m jet-lagged, but really I’m just email-lagged as I try to dig through the few days of messages that I missed in my brief foray to the Emerald Isle over the past few days (which was fantastic, by the way, thanks for asking). […]
Let’s start with a little exercise… this is the pivotal sentiment of the latest pitch from Chris Wood in his ad for Casey’s Extraordinary Technology newsletter: “The Stock Story I’m About To Share With You Is The BIGGEST Of My Entire Career” How often, do you imagine, is something similar said in an ad for […]
Quite a few eagle-eyed Gumshoe readers forwarded the latest ad from Dr. David Eifrig to us over the weekend — he’s pitching his Retirement Millionaire newsletter, which is an “entry level” offering from Stansberry that includes money-saving retirement tips and health tips as well as investment ideas. It tends to not be an aggressive or […]
China-focused stock advisory launched late Summer 2016, initially aimed to profit from Chinese internet stocks that they thought had the potential to rise more rapidly than their US counterparts. Uses different subscription model ($1,500 nonrefundable fee, then $49 a month for as long as you want to keep getting updates).
This ad has been rolling for a week or so, and a group of Gumshoe readers have already been discussing it and trying to figure out exactly what the Stansberry folks are talking about… but there are lots of questions still coming over the transom here at Castle Gumshoe, so let’s take a look. The […]
Nick Giambruno is helming the Crisis Investing letter for Casey Research now, which must come with a fairly high degree of attention because Doug Casey really made his name with his bestselling book of the same name in the late 1970s (later revised a couple times). And after all this time you know what you’re […]
Dave Lashmet has teased a handful of biotech stocks since starting the Stansberry Venture service a couple years ago, and they usually get a lot of attention from our readers — so the new ad from Lashmet today has been forwarded to me dozens of times already. And while I’m not sure we’ll be able […]
I’ve got a few stocks to mention in the medical space this week — one to update that’s in my portfolio, one to confirm as a teaser pick (since folks keep asking) after several Gumshoe readers discussed it last week, and one to note as a teaser idea that’s being pushed pretty heavily (though the […]
A quickie for the gold enthusiasts to discuss today, since several folks have asked about this “special gold fund” in the last week. And yes, it’s not a super-hard one… but it’s pretty timely, and I thought it might be worth batting it around a bit. Here’s the snippet from Stansberry that I got from […]
The following was originally published on November 10 and has not been updated or revised. The teaser ad covered is being circulated again today with a slightly different headline pitch about cellphone royalties, but the balance of the ad (and the teased company) are largely unchanged. —from 11/10/14— Dr. David Eifrig is touting something that […]
We’ve got a good teaser to solve today, but first — a quick plea: This will be our final week of “Gumshoe Gives Back” this year — we will be donating at least half of all the membership contributions received through the rest of this week (until the end of the day on Friday, 12/12) […]
Monthly small cap investing newsletter that aims to have a “venture capital” investing mindset, looking for high-risk opportunities for dramatic gains.
Immunotherapy for cancer has been in the news quite a bit in recent years, with several drugs making an impact on the worst cancers and giving some real hope for future advancement — not a small thing for a basic medical strategy that’s been tested and tweaked for 125 years now by folks following in […]
I hate to continue to write about this small company with great frequency, since it smacks of “talking my book” (it’s a major personal holding), but we have received a lot of questions from readers today about Dan Ferris’ latest pitch, so we’re re-running our previous free article about this one. Last time around, it […]
Famous families and historical fortunes fascinate investors — the idea that these families you know and (sometimes) worship created vast fortune because of one wily speculator way back in the family tree is almost irresistibly interesting. It gives us the feeling that any family can rise up and make a big bet on the way […]
It’s like the Stansberry folks know what appeals to your friendly neighborhood Stock Gumshoe… and they just can’t get enough of our coverage. Every time I turn around lately they’re teasing and promoting a different kind of “royalty” company. And I loves me some royalties. Royalty companies are pretty well understood by most investors — […]
There have been two pretty big promo campaigns about the Alibaba IPO in the last week or so — one from Bill Patalon in an ad for his Private Briefing, and the other from Mike Palmer for Jeff Clark’s S&A Short Report… so I thought we should try to take a look, answer some reader […]
Today we have to put my usual cautionary note up top. The stock Frank Curzio is pitching as the key supplier for “The 20-Second Battery” is ridiculously small. It has already been recommended to his subscribers over at Phase 1 Investor, so presumably they’ve gotten their fill of the stock (he also touted it about […]
Several intrepid readers sent this pitch flying my way while we were digging out of our latest snowstorm, and I figured a nice little panic about an $82 billion “missed opportunity” ought to warm me up. Phase 1 Investor, the big “upgrade” letter from Stansberry & Associates, usually gets our readers attention when they send […]
Over the last several months we’ve seen several ads touting Steve Sjuggerud’s True Wealth Systems, which is apparently a big quantitative screening “supercomputer” that Steve subcontracted to some computer programmers — and which is supposed to identify investing anomalies that he can then write about to his subscribers, who then will profit. And I can’t […]
Investment recommendations generated by quantitative data-crunching system that looks for “anomalies.”
Monthly small cap newsletter, formerly called Penny Stock Specialist. Canceled when Curzio left Stansberry.
Coverage of retirement issues, discounts and deals, and investment strategies and concepts. Not focused solely on being an investment-picking letter but does make recommendations.
Weekly trading service focused on tiny companies.
Weekly trading service that follows insider buying trends to make recommendations, often shorter-term trades.
Focuses on small, potentially explosive growth companies, mostly in mining, tech and biotech. Formerly run by Rob Fannon. Stopped publishing after Curzio left Stansberry, Stansberry now Publishes the similar Stansberry Venture as their high-priced letter.
Options-based service that aims for steady income, generally by selling covered calls but also using other strategies. No longer exists as of our last check in 2017 and Jeff Clark appears not to be working for Stansberry any longer, though Dr. David Eifrig’s Retirement Trader from the same publisher sometimes uses similar options income strategies.
Recommends trades (long and short) based on clinical trials, particularly for smaller pharmaceutical and biotech companies.
Newsletter that recommends bond investments, particularly high yield corporate bonds.
Service that recommends selling puts against “absurdly cheap” stocks.
Monthly newsletter that focuses on high-dividend stocks and similar investments. (Formerly edited by Tom Dyson, who left to found the Palm Beach Letter publications with Mark Ford) This letter was merged into Stansberry’s Income Intelligence letter, edited by Dr. David Eifrig.
This newsletter focuses on commodity-related stocks, including other natural resources beyond just oil. Edited by Matt Badiali for many years before being taken over by Flavious Smith in 2017.
Free daily newsletter from a variety of contributors, mostly editors of S&A newsletters.
Weekly trading service that recommends aggressive short term moves, often with options.
Monthly newsletter that recommends “deep value” stocks.
Monthly newsletter recommends undervalued, “blue chip” and “next boom” stocks.
Monthly newsletter aims to find undervalued, unloved or contrarian investments.